Cryopyrin-associated periodic syndrome natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 18: | Line 18: | ||
*The symptoms of (disease name) typically develop ___ years after exposure to ___. | *The symptoms of (disease name) typically develop ___ years after exposure to ___. | ||
*Muckle-Wells syndrome (MWS), a moderate phenotype of cryopyrin-associated periodic syndrome, manifests with a typical urticarial rash and fever.<ref name="FingerhutováFráňová2019">{{cite journal|last1=Fingerhutová|first1=Šárka|last2=Fráňová|first2=Jana|last3=Hlaváčková|first3=Eva|last4=Jančová|first4=Eva|last5=Procházková|first5=Leona|last6=Beránková|first6=Kamila|last7=Tesařová|first7=Markéta|last8=Honsová|first8=Eva|last9=Doležalová|first9=Pavla|title=Muckle-Wells Syndrome Across Four Generations in One Czech Family: Natural Course of the Disease|journal=Frontiers in Immunology|volume=10|year=2019|issn=1664-3224|doi=10.3389/fimmu.2019.00802}}</ref> | *Muckle-Wells syndrome (MWS), a moderate phenotype of cryopyrin-associated periodic syndrome, manifests with a typical urticarial rash and fever.<ref name="FingerhutováFráňová2019">{{cite journal|last1=Fingerhutová|first1=Šárka|last2=Fráňová|first2=Jana|last3=Hlaváčková|first3=Eva|last4=Jančová|first4=Eva|last5=Procházková|first5=Leona|last6=Beránková|first6=Kamila|last7=Tesařová|first7=Markéta|last8=Honsová|first8=Eva|last9=Doležalová|first9=Pavla|title=Muckle-Wells Syndrome Across Four Generations in One Czech Family: Natural Course of the Disease|journal=Frontiers in Immunology|volume=10|year=2019|issn=1664-3224|doi=10.3389/fimmu.2019.00802}}</ref> | ||
*FCAS, the mildest form of CAPS, present in infancy with recurrent, cold-induced episodes of fever, urticarialike skin rash, arthralgia and conjunctivitis.<ref name="LevyGérard2015">{{cite journal|last1=Levy|first1=R|last2=Gérard|first2=L|last3=Kuemmerle-Deschner|first3=J|last4=Lachmann|first4=H J|last5=Koné-Paut|first5=I|last6=Cantarini|first6=L|last7=Woo|first7=P|last8=Naselli|first8=A|last9=Bader-Meunier|first9=B|last10=Insalaco|first10=A|last11=Al-Mayouf|first11=S M|last12=Ozen|first12=S|last13=Hofer|first13=M|last14=Frenkel|first14=J|last15=Modesto|first15=C|last16=Nikishina|first16=I|last17=Schwarz|first17=T|last18=Martino|first18=S|last19=Meini|first19=A|last20=Quartier|first20=P|last21=Martini|first21=A|last22=Ruperto|first22=N|last23=Neven|first23=B|last24=Gattorno|first24=M|title=Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry|journal=Annals of the Rheumatic Diseases|volume=74|issue=11|year=2015|pages=2043–2049|issn=0003-4967|doi=10.1136/annrheumdis-2013-204991}}</ref> | |||
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | *If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | ||
Revision as of 17:50, 3 July 2019
Cryopyrin-associated periodic syndrome Microchapters |
Differentiating Cryopyrin-associated periodic syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Cryopyrin-associated periodic syndrome natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Cryopyrin-associated periodic syndrome natural history, complications and prognosis |
FDA on Cryopyrin-associated periodic syndrome natural history, complications and prognosis |
CDC on Cryopyrin-associated periodic syndrome natural history, complications and prognosis |
Cryopyrin-associated periodic syndrome natural history, complications and prognosis in the news |
Blogs on Cryopyrin-associated periodic syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of neonatal-onset multisystem inflammatory disease (NOMID) usually develops during infancy, and start with symptoms such as continuous often low-grade fever, skin rash, neurologic involvement, and arthropathy.[1]
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- Muckle-Wells syndrome (MWS), a moderate phenotype of cryopyrin-associated periodic syndrome, manifests with a typical urticarial rash and fever.[2]
- FCAS, the mildest form of CAPS, present in infancy with recurrent, cold-induced episodes of fever, urticarialike skin rash, arthralgia and conjunctivitis.[3]
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of neonatal-onset multisystem inflammatory disease (NOMID) include:[4][5]
- Hydrocephalus and increased intracranial pressure
- Optic nerve atrophy and progressive vision loss
- Cognitive delay
- Deforming arthropathy (30-40% 0f the cases)
- Sensorineural hearing loss
- Renal amyloidosis
- The two latter are observed more commonly among those with Muckle-Wells syndrome (MWS).[6]
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Goldbach-Mansky, Raphaela; Dailey, Natalie J.; Canna, Scott W.; Gelabert, Ana; Jones, Janet; Rubin, Benjamin I.; Kim, H. Jeffrey; Brewer, Carmen; Zalewski, Christopher; Wiggs, Edythe; Hill, Suvimol; Turner, Maria L.; Karp, Barbara I.; Aksentijevich, Ivona; Pucino, Frank; Penzak, Scott R.; Haverkamp, Margje H.; Stein, Leonard; Adams, Barbara S.; Moore, Terry L.; Fuhlbrigge, Robert C.; Shaham, Bracha; Jarvis, James N.; O'Neil, Kathleen; Vehe, Richard K.; Beitz, Laurie O.; Gardner, Gregory; Hannan, William P.; Warren, Robert W.; Horn, William; Cole, Joe L.; Paul, Scott M.; Hawkins, Philip N.; Pham, Tuyet Hang; Snyder, Christopher; Wesley, Robert A.; Hoffmann, Steven C.; Holland, Steven M.; Butman, John A.; Kastner, Daniel L. (2006). "Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition". New England Journal of Medicine. 355 (6): 581–592. doi:10.1056/NEJMoa055137. ISSN 0028-4793.
- ↑ Fingerhutová, Šárka; Fráňová, Jana; Hlaváčková, Eva; Jančová, Eva; Procházková, Leona; Beránková, Kamila; Tesařová, Markéta; Honsová, Eva; Doležalová, Pavla (2019). "Muckle-Wells Syndrome Across Four Generations in One Czech Family: Natural Course of the Disease". Frontiers in Immunology. 10. doi:10.3389/fimmu.2019.00802. ISSN 1664-3224.
- ↑ Levy, R; Gérard, L; Kuemmerle-Deschner, J; Lachmann, H J; Koné-Paut, I; Cantarini, L; Woo, P; Naselli, A; Bader-Meunier, B; Insalaco, A; Al-Mayouf, S M; Ozen, S; Hofer, M; Frenkel, J; Modesto, C; Nikishina, I; Schwarz, T; Martino, S; Meini, A; Quartier, P; Martini, A; Ruperto, N; Neven, B; Gattorno, M (2015). "Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry". Annals of the Rheumatic Diseases. 74 (11): 2043–2049. doi:10.1136/annrheumdis-2013-204991. ISSN 0003-4967.
- ↑ Sibley, Cailin H.; Plass, Nikki; Snow, Joseph; Wiggs, Edythe A.; Brewer, Carmen C.; King, Kelly A.; Zalewski, Christopher; Kim, H. Jeffrey; Bishop, Rachel; Hill, Suvimol; Paul, Scott M.; Kicker, Patrick; Phillips, Zachary; Dolan, Joseph G.; Widemann, Brigitte; Jayaprakash, Nalini; Pucino, Frank; Stone, Deborah L.; Chapelle, Dawn; Snyder, Christopher; Butman, John A.; Wesley, Robert; Goldbach-Mansky, Raphaela (2012). "Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three- and five-year outcomes". Arthritis & Rheumatism. 64 (7): 2375–2386. doi:10.1002/art.34409. ISSN 0004-3591.
- ↑ Hill, Suvimol Chirathivat; Namde, Madjimbaye; Dwyer, Andrew; Poznanski, Andrew; Canna, Scott; Goldbach-Mansky, Raphaela (2006). "Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA)". Pediatric Radiology. 37 (2): 145–152. doi:10.1007/s00247-006-0358-0. ISSN 0301-0449.
- ↑ Kuemmerle-Deschner, Jasmin B.; Koitschev, Assen; Ummenhofer, Katharina; Hansmann, Sandra; Plontke, Stefan K.; Koitschev, Christiane; Koetter, Ina; Angermair, Eva; Benseler, Susanne M. (2013). "Hearing loss in Muckle-Wells syndrome". Arthritis & Rheumatism. 65 (3): 824–831. doi:10.1002/art.37810. ISSN 0004-3591.